TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17520260
Drug: Mud-bath treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath treatment (12 mud packs and thermal baths)
Study: 17590368
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mud-bath treatment)
Study: 17956712
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid 4 mg
Study: 9349604
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg twice daily for 2 weeks
Study: 1347231
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg kg‐1 or 0.10 mg kg‐1
Study: 1347231
Drug: Atracurium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.4 mg kg‐1 or 0.5 mg kg‐1
Study: 29472491
Drug: Monthly sulfadoxine‐pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine‐pyrimethamine and 2 doses of azithromycin (AZI‐SP)
Study: 29472491
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 doses of sulfadoxine‐pyrimethamine)
Study: 29472491
Drug: Monthly sulfadoxine‐pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine‐pyrimethamine
Study: 26899387
Drug: 0.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg calcitriol orally twice a day for 3 days prior to surgery
Study: 26899387
Drug: Selective vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective vitamin D treatment for patients with postoperative hypocalcaemia (control)
Study: 9528716
Drug: Trovafloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (100 mg tablet)
Study: 9528716
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg capsules, 2 capsules)
Study: 7543060
Drug: G‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (10 g/kg/day subcutaneously and daily)
Study: 9605644
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no G‐CSF)
Study: 2702989
Drug: Aminoglutethimide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide (2 x 125 mg, 3 x 125 mg, or 2 x 250 mg daily)
Study: 27332770
Drug: Single induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single induction chemotherapy regimen C (four cycles of vincristine, carboplatin, and temozolomide) followed by marrow-ablative chemotherapy and autologous hematopoietic cell rescue.
Study: 25169040
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion of 2,000 μg sodium selenite immediately prior to surgery, followed by an additional dosage of 2,000 μg at ICU admission, and a further daily supplementation of 1,000 μg up to 10 days or ICU discharge
Study: 25169040
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration at the same time points
Study: 17391565
Drug: Extra-virgin olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-virgin olive oil (EVOO) with 1125 mg polyphenols/kg and 350 mg tocopherols/kg
Study: 12831586
Drug: Protocol II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol II (gonadotrophins started during clomiphene citrate administration)
Study: 6288396
Drug: Enprofylline 2
Normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 2 mg/kg
Study: 6288396
Drug: Enprofylline 2
Normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 2 + 4 mg/kg
Study: 6288396
Drug: Theophylline 9.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 9.2 +/- 0.9 mg/kg
Study: 29265379
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d for 5 days)
Study: 15786486
Drug: Olanzapine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (average dosage 12.3 mg/day)
Study: 11882225
Drug: rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.9 mg.kg‐1
Study: 11882225
Drug: suxamethonium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1.5 mg.kg‐1
Study: 3069238
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Pharmalgen, D. pteronyssinus)
Study: 22719796
Drug: Pharmacy surveillance
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacy surveillance using a web‐based surveillance tool to monitor drug prescribing and kidney function trends.
Study: 16027572
Drug: Levalbuterol 1.25
Normalized name: levalbuterol 1.25 mg/3 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol 1.25 mg via nebulization
Study: 16027572
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol 2.5 mg via nebulization
Study: 8042234
Drug: Double-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug therapy (DT)
Study: 8042234
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (TT)
Study: 27862577
Drug: Ferumoxytol (FE)
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferumoxytol (FE) 4 mg/kg
Study: 27862577
Drug: Ferumoxytol (FE)
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferumoxytol (FE) 2 mg/kg
Study: 25471273
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (CIT) ingestion (500 mg kg(‐1) body mass)
Study: 17136040
Drug: alpha (s1)‐casein
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha (s1)‐casein hydrolysate (150 mg/day for 30 days)
Study: 22687786
Drug: rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 40 mg/day
Study: 9270561
Drug: cM-T412 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: cM-T412 antibody infusion
Study: 2885117
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg daily combined with beta-adrenergic-blocking drugs
Study: 2885117
Drug: Beta-adrenergic-blocking drugs
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic-blocking drugs alone (single therapy)
Study: 21962943
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral misoprostol (OM) and mechanical dilation with a double‐balloon catheter
Study: 21962943
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (OM) only
Study: 21962943
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral misoprostol (OM) and mechanical dilation with a double‐balloon catheter (excluding cases with premature rupture of membranes)
Study: 21962943
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (OM) only (excluding cases with premature rupture of membranes)
Study: 10614032
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg intravenous naloxone administered 2 minutes prior to ECT treatments
Study: 26568032
Drug: Tosedostat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tosedostat (120 mg on days 1-21 or 180 mg continuously) with cytarabine (1 g/m2/d) or decitabine (20 mg/m2/d) every 35 days
Study: 19578230
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human albumin 20% (1 g/kg) one hour before exchange
Study: 16078036
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori (HP) eradication therapy
Study: 16078036
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) monotherapy
Study: 10367046
Drug: Low-dose intermittent
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intermittent MFP (3 months on, 1 month off) with 1000 mg calcium/day (average daily fluoride ion dose of 11.2 mg)
Study: 10367046
Drug: Continuous MFP
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous MFP with 1000 mg calcium/day (20 mg fluoride ions per day)
Study: 10367046
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone (1000 mg/day)
Study: 6780232
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (continuous infusion over 48 hours initiated within 8 hours after onset of symptoms)
Study: 6780232
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (late intervention, therapy begun more than 8 hours after onset of symptoms)
Study: 6780232
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitroglycerin treatment)
Study: 31619359
Drug: Topical amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical amphotericin 0.15% plus CXL
Study: 31619359
Drug: CXL regardless
Normalized name: CXL-1020
DrugBank: CXL-1020 (DB15326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXL regardless of medication
Study: 12198018
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (714 mg/d for 12 months)
Study: 10200128
Drug: Single 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2 g/kg dose of IVGG
Study: 10200128
Drug: Non-IVGG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-IVGG treatment
Study: 10200128
Drug: 400 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/kg per day for 5 consecutive days of IVGG
Study: 1456570
Drug: Prednisone 50
Normalized name: prednisone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 50 mg at 1500 h
Study: 1456570
Drug: Prednisone 50
Normalized name: prednisone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 50 mg at 0800 h
Study: 1456570
Drug: Prednisone 50
Normalized name: prednisone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 50 mg at 2000 h
Study: 3969541
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metolazone
Study: 3969541
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg furosemide
Study: 3969541
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pindolol
Study: 3969541
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hydralazine
Study: 3969541
Drug: Diuretic monotherapy
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic monotherapy (metolazone or furosemide)
Study: 3969541
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three different antihypertensive agents
Study: 31114137
Drug: Probiotics (Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bacillus subtilis and Enterococcus faecium) with esomeprazole 20 mg b.i.d. for 8 weeks
Study: 31114137
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with esomeprazole 20 mg b.i.d. for 8 weeks
Study: 21099198
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl chloride (EC) spray
Study: 17012873
Drug: ChimeriVax-DEN2 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChimeriVax-DEN2 (high dose, 5 log PFU)
Study: 17012873
Drug: ChimeriVax-DEN2 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChimeriVax-DEN2 (low dose, 3 log PFU)
Study: 17012873
Drug: ChimeriVax-DEN2 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChimeriVax-DEN2 (high dose) in YF immune subjects
Study: 14617474
Drug: GnRHa (buserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa (buserelin acetate, 900 microg/day for 10-12 weeks followed by 4 weeks postoperative treatment)
Study: 11063436
Drug: 1 L/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L/d of paper-filtered coffee brewed with 70 g regular ground beans
Study: 8428870
Drug: Methylphenidate in
Normalized name: Product containing methylphenidate in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate in combination with behavioral parent training plus child self-control instruction
Study: 3619741
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of intravenous metoclopramide hydrochloride
Study: 27219616
Drug: Beta-blockers (Metoprolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (Metoprolol, 37±13.5 mg, n=48)
Study: 27219616
Drug: No beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blockers (n=52)
Study: 24593273
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration of itraconazole (ITCZ) - 400 mg/day for 2 days followed by 200 mg/day until day +90 post transplantation.
Study: 24593273
Drug: Short-term administration
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term administration of itraconazole (ITCZ) - 400 mg/day for 2 days followed by 200 mg/day until day +30 post transplantation.
Study: 24593273
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration of itraconazole (ITCZ) from day +30 to day +90.
Study: 24593273
Drug: Short-term administration
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term administration of itraconazole (ITCZ) from day +30 to day +90.
Study: 24593273
Drug: Long-term administration
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term administration of itraconazole (ITCZ) - drug-related adverse events.
Study: 24593273
Drug: Short-term administration
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term administration of itraconazole (ITCZ) - drug-related adverse events.
Study: 22536073
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (2.4 g omega-3, 1800 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid)
Study: 20688775
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (30 mg/kg over 10 minutes in normal saline)
Study: 20688775
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (5 ml over 10 minutes)
Study: 18454609
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion (CSCI) of opioid for 48 hours
Study: 18454609
Drug: Intermittent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent subcutaneous injections (ISCI) of opioid for 48 hours
Study: 10563072
Drug: Perindopril 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4-8 mg
Study: 8690820
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus epoprostenol
Study: 30132926
Drug: Uninterrupted NOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted NOAC therapy
Study: 30132926
Drug: Interrupted NOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted NOAC therapy
Study: 22357633
Drug: Treatment order
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment order B (POWER followed by FTP)
Study: 19071128
Drug: Metyrapone (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (1500 mg)
Study: 12493085
Drug: Low-fat, high-carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-carbohydrate lunch (5.7 g fat)
Study: 7639167
Drug: Complex trials
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex trials designed to improve reperfusion therapy
Study: 28368672
Drug: Intensive arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive arm (idarubicin 9 mg/m2 daily for 3 days)
Study: 28368672
Drug: Standard arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm (idarubicin 9 mg/m2 daily for 2 days)
Study: 25381472
Drug: Ultrasound-guided corticosteroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided corticosteroid injection (40 mg/1 ml methylprednisolone acetate)
Study: 25381472
Drug: Blinded corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded corticosteroid injection (40 mg/1 ml methylprednisolone acetate)
Study: 17062303
Drug: IV pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV pantoprazole 160 mg/d for 3 days
Study: 17062303
Drug: Omeprazole 160
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 160 mg/d for 3 days
Study: 14597860
Drug: Orlistat 360
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 360 mg/day plus hypocaloric diet
Study: 10954007
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (50 mg losartan daily and 10 mg enalapril daily)
Study: 8598621
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of zileuton four times daily
Study: 8598621
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of zileuton, 400 mg of zileuton, or placebo
Study: 1421877
Drug: sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham injections (n = 13)
Study: 27893064
Drug: Lower-protein group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-protein group (1 g of bovine protein/100 mL of breast milk)
Study: 27893064
Drug: Higher-protein group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-protein group (1.8 g of bovine protein/100 mL of breast milk or individualized high-protein supplementation)
Study: 24330475
Drug: LVD-ADV combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVD-ADV combination therapy
Study: 24330475
Drug: ADV monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV monotherapy
Study: 21977923
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 300,000 IU of vitamin D3
Study: 21977923
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin D injection)
Study: 17878495
Drug: Combined thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined thyroxine and triiodothyronine treatment
Study: 2664509
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (325 mg every other day)
Study: 19884558
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) sleep intervention (Individualized Sleep Promotion Plan [ISPP])
Study: 17438255
Drug: Gabapentin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (900 to 3600 mg/d for 8 weeks)
Study: 16294457
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta‐estradiol/0.125 mg trimegestone
Study: 16294457
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17beta‐estradiol/1 mg norethisterone acetate
Study: 16294457
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta‐estradiol/0.5 mg norethisterone acetate
Study: 12040347
Drug: Bivalirudin phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin phase A (1.0 mg/kg bolus, infusion of 2.5 mg/kg/h for 4 hours) plus abciximab
Study: 12040347
Drug: Bivalirudin phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin phase B (0.5 mg/kg bolus, infusion of 1.75 mg/kg/h for the procedure duration) plus provisional abciximab
Study: 12040347
Drug: Bivalirudin phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin phase C (0.75 mg/kg bolus, infusion of 1.75 mg/kg/h for the procedure duration) plus provisional abciximab
Study: 12040347
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus planned abciximab
Study: 9883403
Drug: Paracervical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical anesthesia (10 ml of 1.5 mepivacaine)
Study: 8584295
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg four times a day for 4 weeks
Study: 2122724
Drug: Sorbitol (70%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (70%, 0 to 60 mL daily for 4 weeks)
Study: 27808556
Drug: Parent-Focused Therapy
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Focused Therapy (PFT)
Study: 15727575
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone for 2 weeks and intranasal budesonide for 12 months